Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886785 | 1.00 | MEN1 (0.40) | MEN1MAPK1KMT2ACTSKDPP8 | |
| SCHEMBL29843545 | 0.85 | MEN1 (0.41) | MEN1MAPK1KMT2ACTSKDPP8 | |
| SCHEMBL22644381 | 0.83 | MEN1 (0.38) | MEN1MAPK1KMT2ACTSKDPP8 | |
| SCHEMBL28383493 | 0.83 | MEN1 (0.39) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL6884521 | 0.83 | MEN1 (0.39) | MEN1MAPK1KMT2ACTSKDPP8 | |
| SCHEMBL571503 | 0.81 | CTSK (0.38) | MEN1MAPK1KMT2ACTSKAPLNR | |
| SCHEMBL12070776 | 0.79 | KMT2A (0.37) | MEN1MAPK1KMT2ACTSKDPP8 | |
| SCHEMBL6886778 | 0.79 | CTSK (0.35) | MEN1MAPK1KMT2ACTSKDPP8 | |
| SCHEMBL76972 | 0.78 | CTSK (0.36) | MEN1MAPK1KMT2ACTSKAPLNR | |
| SCHEMBL571320 | 0.78 | CTSK (0.36) | MEN1MAPK1KMT2ACTSKAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853281-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| WO-2010070615-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTSV | MEN1 4333/4885MAPK1 2697/4885KMT2A 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.